Clinical Trial Update: Renal Safety Evaluation After Dotarem®-Enhanced MRI [Phase 4]

View source ↗

Summary

Phase 4 study evaluating renal safety of Dotarem (gadoterate meglumine)-enhanced MRI in patients with renal insufficiency; results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• DOTAREM (Gadoterate meglumine)

Snippet

Sponsor: Guerbet | Conditions: Renal Insufficiency | Phase 4 | Status: COMPLETED | Results posted: 2015-06-09